Analysis of Cytokine Expression Pattern in Systemic Sclerosis (SCLEROKINE)
Primary Purpose
Systemic Sclerosis
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Skin biopsies
Sponsored by
About this trial
This is an interventional basic science trial for Systemic Sclerosis focused on measuring cytokine, skin inflammation
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 year-old
- Diagnosis of systemic sclerosis according to ACR/EURAL 2013 criteria.
- Skin sclerosis reaching an area over finger bases of hands and feet
- Free subject, without neither guardianship, wardship nor subordination
- Patient with Social Security
- Informed and signed consent by the patient after clear and loyal information on the study
Exclusion Criteria:
- Age < 18 year-old
- Patients that do not fit the ACR/EURAL 2013 criteria
- Patients under immunosuppressive treatment
- Sclerosis limited to fingers of hands and feets.
- Patient without Social Security
- Pregnant and nursing women
Sites / Locations
- CHU de Poitiers
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Sclerodermic patients
Arm Description
Sclerodermic patients presenting cutaneous fibrosis
Outcomes
Primary Outcome Measures
Skin IL-34 mRNA expression levels
Skin IL-34 mRNA expression levels (expressed in % of relative expression of GAPDH) in systemic sclerosis patients by comparison with healthy subjects. Skin biopsies are collected at D0 for SSc patients (inclusion day)
Secondary Outcome Measures
Immunostainings against IL-34 and other cytokines on skin sections
Immunostainings against IL-34 and other cytokines on skin sections from systemic sclerosis patients versus healthy skins
Protein expression levels of IL-34 and other cytokines by ELISA
Protein expression levels of IL-34 and other cytokines by ELISA (quantitative study) in plasma and lysates of skin biopsies from systemic sclerosis patients versus
Skin IL-34 mRNA expression levels of other cytokines
Skin IL-34 mRNA expression levels of other cytokines in patients with systemic sclerosis compared to healthy patients.
Full Information
NCT ID
NCT03537105
First Posted
May 15, 2018
Last Updated
April 20, 2020
Sponsor
Poitiers University Hospital
Collaborators
University of Poitiers
1. Study Identification
Unique Protocol Identification Number
NCT03537105
Brief Title
Analysis of Cytokine Expression Pattern in Systemic Sclerosis
Acronym
SCLEROKINE
Official Title
Analysis of Cytokine Expression Pattern in Systemic Sclerosis: Study of the Role of Interleukine-34
Study Type
Interventional
2. Study Status
Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
July 12, 2018 (Actual)
Primary Completion Date
September 4, 2019 (Actual)
Study Completion Date
September 4, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Poitiers University Hospital
Collaborators
University of Poitiers
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
By contrast to other proinflammatory cytokines which are found up-regulated in the skin of patients with psoriasis, atopic dermatitis or systemic sclerosis, IL-34 is the only cytokine that undergoes down-regulation. This finding is interesting regarding the description of IL-34 as an immunosuppressive cytokine. In this study, the expression and the role of interleukin-34 (IL-34) will be investigated in the physiopathology of systemic sclerosis.
Detailed Description
The mechanisms involved in the physiopathology of systemic sclerosis (SSc) are not fully understood, particularly the pattern of cytokine expression in the skin of SSc patients. These cytokines are known to play a central role in the regulation of numerous inflammatory diseases and, among them, IL-34 is the only cytokine which has been found to be down-regulated in other skin inflammatory disorders such psoriasis or atopic dermatitis. IL-34 has been described as an immunosuppressive cytokine, and our preliminary results show that IL-34 is active on fibroblasts, a key cell that undergoes dysfunction in SSc. Thus, we are willing to explore its expression profile in the skin of SSc patients and its potential role in the physiopathology of the disease. For this study, we will analyze IL-34 mRNA levels in the skin and the plasma of SSc patients by comparison to healthy patients. Thirty patients will be included in the Internal Medicine Unit of the CHU de Poitiers during a single visit, in the frame of their medical follow-up, to collect two skin biopsies and 5 ml of blood after obtaining their informed consent. The expression of IL-34 will also be investigated at the protein level by immunostaining on skin sections and by ELISA (skin protein lysates and plasma). Moreover, the expression of other proinflammatory cytokines will be investigated both at the mRNA and protein levels.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Sclerosis
Keywords
cytokine, skin inflammation
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Sclerodermic patients
Masking
None (Open Label)
Allocation
N/A
Enrollment
22 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sclerodermic patients
Arm Type
Experimental
Arm Description
Sclerodermic patients presenting cutaneous fibrosis
Intervention Type
Procedure
Intervention Name(s)
Skin biopsies
Other Intervention Name(s)
Serum collection
Intervention Description
Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
Primary Outcome Measure Information:
Title
Skin IL-34 mRNA expression levels
Description
Skin IL-34 mRNA expression levels (expressed in % of relative expression of GAPDH) in systemic sclerosis patients by comparison with healthy subjects. Skin biopsies are collected at D0 for SSc patients (inclusion day)
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Immunostainings against IL-34 and other cytokines on skin sections
Description
Immunostainings against IL-34 and other cytokines on skin sections from systemic sclerosis patients versus healthy skins
Time Frame
1 day
Title
Protein expression levels of IL-34 and other cytokines by ELISA
Description
Protein expression levels of IL-34 and other cytokines by ELISA (quantitative study) in plasma and lysates of skin biopsies from systemic sclerosis patients versus
Time Frame
1 day
Title
Skin IL-34 mRNA expression levels of other cytokines
Description
Skin IL-34 mRNA expression levels of other cytokines in patients with systemic sclerosis compared to healthy patients.
Time Frame
1 day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 year-old
Diagnosis of systemic sclerosis according to ACR/EURAL 2013 criteria.
Skin sclerosis reaching an area over finger bases of hands and feet
Free subject, without neither guardianship, wardship nor subordination
Patient with Social Security
Informed and signed consent by the patient after clear and loyal information on the study
Exclusion Criteria:
Age < 18 year-old
Patients that do not fit the ACR/EURAL 2013 criteria
Patients under immunosuppressive treatment
Sclerosis limited to fingers of hands and feets.
Patient without Social Security
Pregnant and nursing women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-François Jégou, PhD
Organizational Affiliation
University of Poitiers
Official's Role
Study Director
Facility Information:
Facility Name
CHU de Poitiers
City
Poitiers
Country
France
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Analysis of Cytokine Expression Pattern in Systemic Sclerosis
We'll reach out to this number within 24 hrs